New insider activity at PTC Therapeutics ( (PTCT) ) has taken place on January 8, 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Several top executives at PTC Therapeutics have recently sold notable amounts of company stock, collectively cashing out substantial sums. CBO Eric Pauwels sold 3,141 shares for $242,416, while Chief Technical Ops Officer Neil Gregory Almstead sold 2,411 shares worth $186,097. EVP & Chief Medical Officer Lee Scott Golden disposed of 1,982 shares for $152,855, and SVP & CAO Christine Marie Utter sold 2,616 shares totaling $201,918. CEO Matthew B. Klein led the group in volume, selling 8,165 shares for $629,895, and CFO Pierre Gravier sold 2,139 shares for $164,596. Together, these insider sales highlight a significant wave of stock transactions across PTC Therapeutics’ senior leadership team.
Recent Updates on PTCT stock
In the last 24 hours, PTC Therapeutics drew positive attention after Morgan Stanley raised its price target, driven not by a single company-specific event but by a broader 2026 outlook favoring U.S. small- and mid-cap biotechs. The analyst expects these companies, including PTC, to shift from being heavy consumers of capital to becoming generators of cash flow, especially as large-cap biopharma faces a significant patent cliff that may redirect investor interest toward smaller commercial-stage names. Company-specific developments also supported sentiment: PTC fully monetized its remaining Evrysdi royalty interest via an amended agreement with Royalty Pharma, trading future royalty income for substantial upfront and potential milestone cash to strengthen its balance sheet, and it secured Japanese approval of Sephience for phenylketonuria across all ages and disease severities, with pricing negotiations underway ahead of a planned 1Q 2026 launch. These factors, along with an earnings call perceived as strong and a view that the stock remains undervalued despite high leverage and pressured free cash flow, underpinned the recent positive reassessment of the stock’s prospects and helped support a constructive technical and fundamental outlook over the near term.
Spark’s Take on PTCT Stock
According to Spark, TipRanks’ AI Analyst, PTCT is a Neutral.
The score is driven by strong operational momentum (high TTM revenue growth, strong margins, and positive earnings-call guidance around Sephience) and an inexpensive P/E. Offsetting factors are balance-sheet risk from negative equity/high leverage and only neutral technical momentum.
To see Spark’s full report on PTCT stock, click here.
More about PTC Therapeutics
YTD Price Performance: 1.69%
Average Trading Volume: 1,533,375
Technical Sentiment Signal: Buy
Current Market Cap: $6.16B